menu
    • menu

    Company profile for Illimis Therapeutics

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Illimis Therapeutics is a Korean platform-based biotech company focused on developing chimeric fusion protein therapies for neurodegenerative diseases, including Alzheimer’s. Our proprietary platform stands out by addressing the limitations of current antibody-based treatments, particularly the risks of neuroinflammation and ARIA (Amyloid-Related Imaging Abnormalities). Unlike traditional therapies that rely on Fc receptor-m...
    Illimis Therapeutics is a Korean platform-based biotech company focused on developing chimeric fusion protein therapies for neurodegenerative diseases, including Alzheimer’s. Our proprietary platform stands out by addressing the limitations of current antibody-based treatments, particularly the risks of neuroinflammation and ARIA (Amyloid-Related Imaging Abnormalities). Unlike traditional therapies that rely on Fc receptor-mediated microglial phagocytosis, our approach leverages the TAM receptor, a novel phagocytic pathway on glial cells, offering a safer and more targeted mechanism for clearing pathological proteins in the brain.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Illimis Therapeuticskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    2F&3F, 18, Heolleung-ro 569-gil, Gangnam-gu, Seoul 06376
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.illimistx.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/illimis-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Illimis Raises $42M Series B for CNS, Immune Drugs
    Illimis Raises $42M Series B for CNS, Immune Drugs

    14 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/illimis-therapeutics-closes-58-billion-krw-42-million-series-b-financing-to-accelerate-cns-and-immune-disease-drug-development-via-gaia-platform-302504123.html

    PR NEWSWIRE
    14 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search